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cal Global Impression scores at week 12 were compared be-
tween groups. The present open trial presents a new promis-
ing pharmacotherapy for tinnitus that should be validated in 
placebo-controlled double-blind trials. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Tinnitus is a phantom phenomenon in which a patient 
has a conscious hearing perception that can take the form 
of ringing, buzzing, roaring or hissing (among others) in 
the absence of an external sound [Eggermont and Rob-
erts, 2004; Moller, 2007a]. Many people have experienced 
ringing in their ears when no external sound is present 
[Moller, 2007a]. However, in 5–15% of the general popula-
tion, the tinnitus sensation is unremitting [Eggermont 
and Roberts, 2004]. It is estimated that for 1 in 100 of the 
general population, the condition severely affects their 
quality of life, since it is accompanied by a variety of 
symptoms including hyperacusis (lowered tolerance to 
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 Abstract 
 Tinnitus, the phantom perception of sounds, is a highly prev-
alent disorder. Although a wide variety of drugs have been 
investigated off label for the treatment of tinnitus, there is 
no approved pharmacotherapy. We report an open-label ex-
ploratory pilot study to assess the effect of muscle relaxants 
acting on the central nervous system on tinnitus patients. 
Cyclobenzaprine at high (30 mg) and low doses (10 mg), or-
phenadrine (100 mg), tizanidine (24 mg) and eperisone (50 
mg) were administered to a maximum of 20 patients per 
group over a 12-week period. High-dose cyclobenzaprine re-
sulted in a significant reduction in the Tinnitus Handicap In-
ventory (THI) score between baseline and week 12 in the
intention-to-treat sample. On the other hand, other treat-
ments were not effective. These results were confirmed in an 
explorative analysis where baseline corrected THI and Clini-
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sound), phonophobia (fear of sound), anxiety, depression, 
irritability, agitation, stress, insomnia and even leading 
to suicide attempts in severe cases [Moller, 2007a]. 
 The available treatments for the management of the 
tinnitus patient are diverse and for most of them some 
patients benefit to some degree [Darlington and Smith, 
2007; Dobie, 1999; Dohrmann et al., 2007; Elgoyhen and 
Langguth, 2010; Goodey, 2007; Jastreboff and Jastreboff, 
2006; Langguth et al., 2006; Langguth et al., 2009; Pat-
terson and Balough, 2006; Van de Heyning et al., 2008]. 
However, any particular treatment does not benefit all 
patients, most likely due to different underlying patho-
physiologies. In addition, some fraction of patients is left 
untreated. Thus, tinnitus is still today a clinically unmet 
need, and many patients would welcome a drug which 
reduces or even abolishes their phantom sound. Al-
though over 4 million prescriptions are written each 
year for tinnitus relief in Europe and the USA, these are 
all off-label prescriptions from a wide variety of thera-
peutic drugs, and there is currently not a single FDA- 
or EMA-approved drug on the market [Elgoyhen and 
Langguth, 2010; Langguth et al., 2009; Vio and Holme, 
2005].
 Tinnitus is a symptom that is associated with virtu-
ally all diseases and disorders affecting the auditory sys-
tem and can arise from a lesion in any part of the audi-
tory pathway. While the initial lesion might affect the pe-
ripheral organ of the auditory system, the neural correlate 
of the sound perceived is most likely in the central ner-
vous system [Eggermont and Roberts, 2004]. Although 
the mechanisms underlying tinnitus are far from being 
fully understood, there is growing evidence that changes 
in neuronal activity, neuronal synchrony, disruption of 
the balance between excitation and inhibition and rear-
rangements of the tonotopic organization in different 
parts of the auditory pathway, including the dorsal co-
chlear nucleus, inferior colliculus, thalamus and/or audi-
tory cortex, underlie tinnitus pathology [Bauer et al., 
2008; Eggermont and Roberts, 2004; Kaltenbach and 
Godfrey, 2008; Melcher et al., 2000; Schlee et al., 2009a; 
Smits et al., 2007]. Moreover, tinnitus is not a static con-
dition and probably involves multiple dynamic brain net-
works, which extend beyond the primary sensory corti-
ces [De Ridder et al., 2011; Schlee et al., 2008, 2009a, b]. 
Faced with this lack of deep understanding of the patho-
physiology of tinnitus, a priori any drug acting on the 
nervous system becomes a potential compound to be 
tried in tinnitus patients. A considerable number of drugs 
have been evaluated in clinical trials [Elgoyhen and Lang-
guth, 2010; Langguth et al., 2009; Vio and Holme, 2005]. 
Although some subgroups of patients present positive re-
sults, they are not always clearly identified and most trials 
have demonstrated no replicable long-term reduction of 
tinnitus in most of the patients, with an effect superior to 
placebo [Dobie, 1999; Elgoyhen and Langguth, 2010; 
Langguth et al., 2009]. In the absence of effective tools 
towards identifying subgroups of patients to be included 
in well-designed placebo-controlled clinical trials, an 
open-trial design should be considered as a prior step 
[Dobie, 1999; Landgrebe et al., 2011a].
 The aim of the present work was to analyze and com-
pare the effect of several centrally acting muscle-relaxant 
drugs on tinnitus patients: cyclobenzaprine, orphena-
drine, tizanidine and eperisone. These compounds were 
chosen since either there exist no previous reports for 
their use in tinnitus (cyclobenzaprine and tizanidine) or 
just isolated cases (orphenadrine [Abdul-Baqi, 2004] and 
eperisone [Murai et al., 1992]) have been published. 
Moreover, they all have a central nervous system mecha-
nism of action and have been used in the treatment of 
different forms of pain [Cabitza and Randelli, 2008; Chau 
et al., 1998; Desaphy et al., 2009; Hunskaar and Donnell, 
1991; Ishizuki and Yanagisawa, 1992; Kino et al., 2005; 
Kobayashi et al., 1996; Kornhuber et al., 1995; Leite et al., 
2009; Sayers et al., 1980; Yang et al., 2011], a disorder that 
has some striking pathophysiological similarities with 
tinnitus [De Ridder et al., 2011; Moller, 2007b].
 Patients and Methods 
 Five different treatments were offered to patients attending 
tinnitus clinics in Lajeado, Brazil (orphenadrine, tizanidine, 
high-dose cyclobenzaprine) and Regensburg, Germany (low-dose 
cyclobenzaprine, eperisone). Subjects enrolled between February 
2008 and March 2010 were screened according to general inclu-
sion and exclusion criteria as indicated in  table 1 . Additional spe-
cific criteria for each treatment are given in  table 2 . Subjects en-
rolled were clinical patients seeking help because of their tinnitus 
who were informed of their option to participate in the study.
 Patients were informed about the nature, purpose and poten-
tial risks of this individualized healing attempt and gave written 
informed consent to this procedure, which was performed ac-
cording to the declaration of Helsinki. Patient data was kept con-
fidential throughout all further analyses, which have been ap-
proved by the local ethics committee (Ethikkommission an der 
Universität Regensburg).  
 Prospective assessment of treatment effects was performed 
using standardized procedures as established in the Tinnitus Re-
search Initiative database [Landgrebe et al., 2011b]. This follows 
the consensus for patient assessment and outcome measurement 
found by tinnitus experts from many countries during an inter-
national tinnitus conference in Regensburg, Germany in 2006 
[Langguth et al., 2007]. The core assessments consisted of a stan-
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dardized detailed tinnitus and medical history (Tinnitus Sample 
Case History Questionnaire), otological examination, psycho-
acoustic measures of tinnitus (pitch match and minimal masking 
level), a validated questionnaire for the assessment of tinnitus 
severity (Tinnitus Handicap Inventory, THI), and the subjective 
Clinical Global Impression score (CGI). Hearing thresholds were 
performed at 500 Hz, 1, 2, 3 and 4 kHz. In patients with asym-
metric hearing loss and/or unilateral tinnitus, the presence of a 
tumor was excluded by magnetic resonance imaging. Treatment 
duration was 12–14 weeks ( table  3 ). Patients were assessed at 
weeks 2, 4, 8, 12 and 16 with the THI, CGI and clinically moni-
tored for the presence of adverse effects. When moderate to se-
vere side effects were observed, patients were removed from the 
trial. Tinnitus pitch and minimal masking level were repeated at 
week 12 in a subgroup of patients. In the orphenadrine, tizani-
dine and high-dose cyclobenzaprine groups, medication was up-
titrated over the first 4 weeks in order to reduce possible side ef-
fects, and then downtitrated from week 12 to 14, so as to prevent 
rebounds. Dose regimens for the different groups are indicated 
in  table 3 . 
Table 1. G eneral inclusion and exclusion criteria
Inclusion criteria General exclusion criteria
Primary complaints of chronic 
tinnitus >5 months
Treatable otological disorder
Age between 18 and 75 years Serious or unstable medical 
or psychiatric condition 
Tinnitus Handicap Inventory
scores at screening ≥20
Pregnancy or breast-feeding
Normal magnetic resonance 
imaging of the pontine angle in the 
presence of unilateral tinnitus or 
asymmetric hearing thresholds
Alcohol or drug abuse
Willingness to receive the pro-
posed drug as treatment and
to complete the assessments
Hypersensitivity to the 
medication or any 
component of the product 
Table 2. S pecific exclusion criteria for each compound
Compound  Exclusion criteria 
Orphenadrine Cardiospasm, glaucoma, myasthenia gravis, 
prostatic hypertrophy or obstruction of bladder 
neck, pyloric or duodenal obstruction, stenos-
ing peptic ulcer, cardiac arrhythmias and/or 
 decompensation, coronary insufficiency, 
 tachycardia, concomitant use of propoxyphene
Tizanidine Concomitant use of ciprofloxacin, fluvoxamine, 
CYP1A2 inhibitors and antihypertensive 
therapy, liver and renal impairment 
Cyclo-
benzaprine 
Cardiac problems, arrhythmias, cardiac con-
duction disturbances, heart block, congestive 
heart failure and myocardial infarction within 
1 year of study, hyperthyroidism, glaucoma, 
concomitant use of monoaminoxidase inhibi-
tors, hepatic impairment and urinary retention 
Eperisone Hepatic impairment 
Table 3.  Treatment schedule (mg/day)
Medication Week 1 Week 2 Week 3 Week 4 Weeks 5–11 Week 12 Week 13 Week 14 Weeks 15–16
Orphenadrine 100 100 200 200 200 200 100 100 –
Tizanidine 8 12 16 24 24 16 12 8 –
Cyclobenzaprine (high dose) 15 15 22.5 30 30 30 22.5 15 –
Cyclobenzaprine (low dose) 10 10 10 10 10 10 – – –
Eperisone 50 50 50 50 50 50 – – –
Table 4. N umber of subjects screened, allocated to treatment and 
completing treatment
Drug trial Screened Allocated 
to treat-
ment
Dropped 
out
Com-
pleted
the trial
Orphenadrine 35 18 6 (5) 12
Tizanidine 30 11 8 (4) 3
Cyclobenzaprine (high dose) 30 15 1 (1) 14
Cyclobenzaprine (low dose) 16 12 6 (5) 6
Eperisone 25 201 6 (1) 14
F igures in parentheses indicate dropouts because of adverse 
effects.
1 Statistics were done for 19 patients as 1 patient had not filled 
out at least 1 tinnitus handicap questionnaire completely (>20% 
of items missing).
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 The main outcome measurement was the difference in the THI 
score between week 12 and baseline in the intention-to-treat sam-
ple. That means that missing data were replaced by the last obser-
vation carried forward and backward approach in data sets with 
at least 1 THI score. For the primary outcome paired Student t tests 
for the particular treatment groups were performed including ef-
fect sizes (d) according to Cohen [1988]. As the five treatment 
groups were independent and also from different centers, analyses 
including all treatment groups and comparisons between treat-
ment groups were marked as explorative. In explorative analyses, 
baseline-corrected THI scores at week 12 (baseline minus week 12) 
were compared by an analysis of variance (ANOVA) with the be-
tween-subjects factor ‘treatment group’. The same ANOVA was 
done for CGI, which was used as a secondary outcome variable. 
Additionally,   2 tests of independence for the variables ‘treatment 
group’ and ‘positive treatment response’ were calculated. Accord-
ing to recent findings, positive response was defined as a mini-
mum THI change of 7 points [Zeman et al., 2011]. Furthermore, 
an ANOVA with the between-subjects factor ‘treatment group’ 
and the within-subjects factor ‘time’ (7 levels: screening, baseline, 
week 2, week 4, week 8, week 12, week 16) was performed. 
 Treatment groups were compared at baseline for age, gender, 
tinnitus laterality, tinnitus duration, mean hearing level, minimal 
masking level, number of previous treatments, somatic modula-
tion of tinnitus and suffering from neck pain, by separate ANO-
VAs or   2 tests. Whenever differences across groups were ob-
served (p  ! 0.2), the potential influences of these parameters on 
treatment outcome were evaluated by correlation analyses, ANO-
VAs or   2 tests.
 Results 
 Tolerability and Side Effects 
 The total numbers of subjects screened, those allocat-
ed to treatment, and those completing treatment, are giv-
en in  table 4 . The sample characteristics for each treat-
ment are shown in  table 5 .
 Reported adverse effects differed according to the ad-
ministered treatment. Patients of the high-dose cyclo-
benzaprine group complained of dry mouth, sleepiness 
and constipation. One subject suffered from severe con-
stipation, and treatment was stopped at week 8. Low-dose 
cyclobenzaprine patients reported dry mouth, weight 
gain, tiredness, constipation, hypertension (1 dropout), 
cardiac long Q–T interval syndrome (1 dropout), gout, 
urinary retention, reflux, sexual dysfunction, dizziness, 
lightheadedness and increased tinnitus (1 dropout). Be-
side the 3 patients mentioned above with the declara-
tion of particular dropout reasons, 3 additional patients 
stopped treatment because of several adverse events (2 
patients) or without specification of reasons (1 patient). 
Patients receiving orphenadrine mentioned dry mouth, 
hand tremor, gastric discomfort, nausea, dizziness and 
somnolence. In 5 patients treatment was stopped because 
of adverse effects, and in all cases side effects disappeared 
after the drug had been suspended. In the tizanidine 
group, side effects were frequent and responsible for most 
of the dropouts (5/11). They included: sleepiness, dizzi-
ness, dry mouth, visual hallucination, weakness, agita-
tion, insomnia cramps and hypotension. All subjects
immediately recovered when medication was removed. 
Eperisone side effects were headache, tiredness, sexual 
dysfunction, insomnia, agitation, hypertension, elevated 
liver enzymes and increased tinnitus (1 dropout). One 
additional patient stopped treatment because of lack of 
improvement and 4 further patients dropped out without 
specification of reasons. 
 Primary Outcome 
 High-dose cyclobenzaprine (T = 6.8; d.f. = 12; p  ! 
0.001; d = 1.742) but not low-dose cyclobenzaprine (T = 
Table 5. S ample characteristics with statistics for group differences as indicated by ANOVAs or 2 tests of independence
Orphen-
adrine
Tizani-
dine
Cyclobenzaprine
(high dose)
Cyclobenzaprine
(low dose)
Eperisone p
Age, years 50812 51810 55811 55810 49810 0.435
Females/males 13/5 6/5 8/7 3/9 5/14 0.030
Tinnitus duration, months 99885 55859 1728148 1478107 66879 0.010
Number of previous treatments (0/1/>1) 3/6/9 4/1/6 0/2/12 0/1/11 0/0/19 0.001
Tinnitus laterality (bilateral and head/unilateral) 7/11 7/4 10/5 8/4 13/6 0.347
Somatic modulation of tinnitus (no/yes/don’t know) 14/3/1 10/1/0 10/5/0 7/5/0 9/10/0 0.167
Suffering from neck pain (yes/no) 9/9 3/7 4/11 4/7 1/18 0.051
Minimal masking level, dB HL 48818 45816 46815 53818 55822 0.678
Mean hearing level, dB HL 27814 24814 32810 28826 16812 0.126
Figures are numbers or means 8 SD.
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1.1; d.f. = 11; p = 0.281; d = 0.121) resulted in a significant 
reduction in THI score from baseline to week 12. Neither 
orphenadrine (T = 1.7; d.f. = 17; p = 0.117; d = 0.427) nor 
tizanidine (T = 2.0; d.f. = 10; p = 0.080; d = 0.161) nor 
eperisone (T = 0.9; d.f. = 18; p = 0.377; d = 0.087) showed 
a significant reduction of THI scores. Overall THI effects 
are depicted in  figure 1 .
 Explorative Analyses 
 The ANOVA for baseline-corrected THI change at 
week 12 showed a significant treatment group main effect 
(F = 8.9; d.f. = 4.70; p  ! 0.001). Bonferroni-corrected post 
hoc tests indicated a more pronounced THI reduction for 
high-dose cyclobenzaprine compared to all other medi-
cations (orphenadrine: p = 0.005, d = 1.048; tizanidine:
p = 0.004, d = 1.731; eperisone: p  ! 0.001, d = 2.115; low-
dose cyclobenzaprine: p = 0.001, d = 1.719). All other post 
hoc contrasts were not significant. Differences in treat-
ment outcome were confirmed by comparison of the 
number of responders (  2 = 24.1; d.f. = 4; p  ! 0.001). High-
dose cyclobenzaprine had a higher number of treatment 
responders (14 out of 15) compared to all other treatment 
groups (orphenadrine: 7 out of 18; tizanidine: 4 out of 11; 
eperisone: 2 out of 19; low-dose cyclobenzaprine: 5 out
of 12). Individual THI variation scores from baseline to 
week 12 are described in  figure 2 .
 The ANOVA for CGI revealed a significant main effect 
of treatment group (F = 6.7; d.f. = 4.57; p  ! 0.001). Bon-
ferroni-corrected post hoc tests indicated a more pro-
nounced improvement for high-dose cyclobenzaprine 
compared to eperisone (p  ! 0.001) and low-dose cyclo-
benzaprine (p = 0.020). In this analysis orphenadrine was 
also superior to eperisone (p = 0.026). All other post hoc 
contrasts were not significant.  
 The ANOVA for all time points and for the THI 
showed a significant time-by-treatment group interac-
tion effect (F = 5.2; d.f. = 24, 420; p  ! 0.001). Bonferroni-
corrected post hoc tests demonstrated that the high-dose 
cyclobenzaprine lowered THI scores for week 2, week 4, 
week 8, week 12 and week 16 in contrast to screening and 
baseline (all p values  ! 0.009). All other treatments showed 
no significant within-group differences between the sep-
arate time points. Post hoc between-group contrasts 
showed treatment effects for high-dose cyclobenzaprine 
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 Fig. 1. THI scores for all treatment groups 
and all time points. 
 Fig. 2. Individual THI scores at baseline and at week 12. Dotted 
line = No change in THI; continuous line = response rate indi-
cated by a reduction of at least 7 points in the THI scores from 
baseline to week 12. 
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compared to tizanidine (p = 0.011) at week 4, and com-
pared to eperisone at week 12 (p = 0.025) and at week 16 
(p = 0.032).
 Groups were comparable for age, minimal masking 
level and tinnitus laterality. Groups were not comparable 
(p  ! 0.2) for gender, tinnitus duration, mean hearing lev-
el, number of previous treatments, somatic modulation of 
the tinnitus and suffering from neck pain ( table 5 ). 
 Analyses indicated no influence of tinnitus duration 
and mean hearing level on medication effects. In none of 
the treatment groups were correlations between baseline-
corrected THI change at week 12 (baseline minus week 
12) and tinnitus duration (–0.214  ! r values  ! 0.045; all
p values  1 0.378) significant, nor were the correlations
between baseline-corrected THI change at week 12 and 
mean hearing levels (–0.249  ! r values  ! 0.186; all p val-
ues  1 0.371). Gender had no effect on treatment outcome 
either (baseline-corrected THI change), as unpaired Stu-
dent t tests between females and males indicated no sig-
nificant differences for all treatment groups (all T values 
 ! 1.4; all p values  1 0.190). The same was found for somat-
ic modulation of tinnitus (all T values  ! 1.3; all p values 
 1 0.326) and for suffering from neck pain (all T values 
 ! 1.5; all p values  1 0.167), except for the low-dose cyclo-
benzaprine group. In this group patients with neck pain 
had a higher benefit from cyclobenzaprine than those 
without neck pain (T = 2.3; d.f. = 9; p = 0.048). An ANO-
VA with the between-group factors ‘number of previous 
treatments’ (0, 1 and  1 1) and ‘treatment groups’ indicated 
no significant main (F = 1.8; d.f. = 2.62; p = 0.171) or in-
teraction effect (F = 0.8; d.f. = 4.62; p = 0.551) for the num-
ber of previous treatments. 
 Discussion 
 The main finding of the present work is that the mus-
cle relaxant cyclobenzaprine, at a dose of 30 mg/day, re-
duced tinnitus severity in a group of tinnitus patients. On 
the other hand, a low dose of cyclobenzaprine (10 mg) as 
well as the muscle relaxants tizanide, orphenadrine and 
eperisone were not effective. The effect of the high dose 
of cyclobenzaprine on tinnitus severity was significant 
when analyzing the primary outcome measurement, the 
difference in the THI score between week 12 and base-
line, in the intention-to-treat sample. These results were 
confirmed in the explorative analysis where baseline-
corrected THI scores at week 12 were compared between 
groups. Moreover, the comparison of the number of re-
sponders gave higher numbers for high-dose cyclobenza-
prine than for each one of the other treatments. Enhanced 
effects of high-dose cyclobenzaprine over low-dose cyclo-
benzaprine and eperisone were also observed when ana-
lyzing the secondary outcome measurement, the changes 
in CGI.
 The fact that the cyclobenzaprine low-dose treatment 
had no beneficial response might indicate that effective 
concentrations of cyclobenzaprine are not achieved with 
lower doses of cyclobenzaprine. This is similar to what 
has been described for pain disorders, where a 30 mg/day 
dosing regimen of cyclobenzaprine is pharmacologically 
effective [Browning et al., 2001; Landy et al., 2011; Malan-
ga et al., 2009]. The observation that fewer side effects and 
fewer dropouts were reported by patients in the cycloben-
zaprine high-dose trial when compared to low-dose cy-
clobenzaprine might reflect the fact that the drug was 
effective in reducing tinnitus in the former and therefore 
patients disregarded side effects.
 Tinnitus can result from an initial insult to the inner 
ear which leads to hair cell death, deafferentation and 
tonotopic reorganization of central auditory pathways 
[Eggermont, 2007; Eggermont and Roberts, 2004]. Thus, 
noise-induced inner ear trauma which leads to hearing 
loss is also one of the main known causes of tinnitus [Ca-
cace, 2006; Elgoyhen and Langguth, 2010; Helfer et al., 
2011]. Therefore, one could a priori propose that the high-
er the hearing loss, the more important the initial damage 
to the sensory auditory epithelium and therefore the 
higher the tinnitus severity [Mazurek et al., 2010]. In this 
regard, the cyclobenzaprine high-dose tinnitus group 
had the highest degree of hearing loss. However, this was 
unrelated to the severity of tinnitus since THI scores at 
baseline did not differ among the different groups. More-
over, the individual extent of hearing loss within the cy-
clobenzaprine high-dose group was not correlated with 
treatment response.
 It has been observed that tinnitus is more resistant to 
treatment the longer the duration of the pathology. This 
has been reported for microvascular decompressions [De 
Ridder et al., 2004, 2007] as well as for transcranial mag-
netic stimulation [De Ridder et al., 2005; Kleinjung et al., 
2007] and correlates with the fact that the tinnitus brain 
network is not static and changes with time [Schlee et al., 
2009a]. The effectiveness of high-dose cyclobenzaprine is 
unrelated to the duration of tinnitus in affected patients 
since the mean duration was the longest in this group of 
patients and, in addition, there was no significant correla-
tion between tinnitus duration and treatment response. 
 Tinnitus is not only the result of changes in the audi-
tory pathway. Recent studies suggest that it is more com-
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plex and multimodal than originally thought [De Ridder 
et al., 2011; Eggermont, 2007; Eggermont and Roberts, 
2004]. Thus cross-modal interactions of the somatic and 
auditory system in the midbrain and brainstem have been 
described [Dehmel et al., 2008], e.g. projections from the 
trigeminal nuclear complex to the cochlear nucleus [Zhou 
and Shore, 2004]. In this regard, tinnitus can be evoked 
or modulated by neural inputs coming from the somato-
sensory, somatomotor and visual-motor systems in some 
individuals [Levine et al., 2003; Sanchez et al., 2002, 
2007]. In particular, the psychoacoustic parameters of 
tinnitus can be modulated by muscle contractions of the 
head, neck and limbs [Koskinen et al., 1980; Kuttila et al., 
2005], pressure of myofacial trigger points [Bezerra Ro-
cha et al., 2008; Rocha and Sanchez, 2007], cutaneous 
stimulation of the hand or fingerprint region and face 
[Cacace et al., 1999], electrical stimulation of the medial 
nerve and hand [Moller and Rollins, 2002], finger move-
ments [Cullington, 2001], orofacial movements [Pinchoff 
et al., 1998] and pressure applied to the temporomandib-
ular joint or lateral pterygoid muscle [Bjorne, 1993; Ru-
binstein, 1993]. Cyclobenzaprine is a muscle relaxant, 
and animal studies have shown that it activates locus coe-
ruleus neurons, leading to an increased release of nor-
adrenaline in the ventral horn of the spinal cord and the 
subsequent inhibitory action of noradrenaline on   -mo-
toneurons [Commissiong et al., 1981]. Thus, one could 
propose that the decrease in tinnitus severity observed in 
the high-dose cyclobenzaprine group is the result of an 
interaction with the somatosensory system. However, an 
interaction between neck pain and treatment response 
was only observed for the low-dose cyclobenzaprine 
group. In the other treatment groups there was no corre-
lation between somatic modulation or neck pain and ben-
efit from treatment. Moreover, the fact that the other 
muscle relaxants orphenadrine, tizanidine and eperisone 
were ineffective most likely indicates that muscle relax-
ation is not the underlying mechanism of the cycloben-
zaprine effect. In addition, other centrally acting muscle 
relaxants such as flupirtine and baclofen have failed to 
demonstrate beneficial effects on tinnitus [Salembier et 
al., 2006; Westerberg et al., 1996].
 The mechanism of action underlying the beneficial ef-
fect of cyclobenzaprine on tinnitus is at present unknown 
and cannot be inferred from the present study. The struc-
ture of cyclobenzaprine is related to that of amiptripty-
line [Lofland et al., 2001], a tricyclic antidepressant. An-
tidepressants have long been used for the treatment of 
tinnitus. Due to their beneficial effects on chronic pain 
syndromes [Mico et al., 2006], particular interest has 
been paid to tricyclic antidepressants. For example, one 
study has compared amitriptyline with placebo and 
found that after 6 weeks of 100 mg amitriptyline there is 
a significant reduction of tinnitus complaints and tinni-
tus loudness compared to the placebo group [Bayar et al., 
2001]. The reason for such a large use of antidepressants 
can be found in the well-described comorbidity between 
depressive disorders and tinnitus [Langguth et al., 2011]. 
In most cases, relief of tinnitus is best achieved in patients 
with depressive symptoms [Sullivan et al., 1993]. The fact 
that no major depressive symptoms were described in the 
patients included in the study makes an antidepressant 
mechanism of action highly improbable as an explana-
tion for the cyclobenzaprine effect on tinnitus, even if 
such an explanation cannot be entirely excluded. 
 The structure of cyclobenzaprine is also related to that 
of cyproheptadine [Honda et al., 2003], an antagonist of 
histamine H 1 receptors, muscarinic acetylcholine recep-
tors, and 5-HT 2A serotonin receptors [Blackshear et al., 
1983; Orzechowski et al., 2005; Watemberg et al., 1999; 
Wolf and Schunack, 1996]. An antagonistic effect of cy-
clobenzaprine on 5-HT 2 receptors has been described 
[Honda et al., 2003; Kobayashi et al., 1996]. Animal stud-
ies have shown that muscarinic antagonists suppress 
salicylate-induced plasticity in the auditory cortex and, 
therefore, might be effective in suppressing the tinnitus 
[Wallhausser-Franke et al., 2006]. On the other hand, it 
has been suggested that the perception of tinnitus could 
be linked to a dysfunction of serotonin transmission at 
one or more levels in the central nervous system [Simp-
son and Davies, 2000] and auditory stimulus processing 
has been associated with serotonergic function [Gallinat 
et al., 2003]. 
 Hyperactivity of the dorsal cochlear nucleus has been 
reported in animal models of tinnitus [Kaltenbach, 2006]. 
Dorsal cochlear nucleus fusiform cells receive inputs 
from noradrenergic neurons in the locus coeruleus [Jones 
and Yang, 1985; Thompson et al., 1995]. Stimulation of 
the locus coeruleus causes changes in the level of activity 
in the dorsal cochlear nucleus [Chikamori et al., 1980]. 
There is evidence indicating that the locus coeruleus 
plays a role in promoting selective attention and orienta-
tion to sensory stimuli [Aston-Jones and Bloom, 1981; 
Rajkowski et al., 2004]. Cyclobenzaprine decreases the 
spontaneous firing rate of locus coeruleus neurons 
[Barnes et al., 1980], which might in part explain the ef-
fects of this compound in tinnitus patients.
 In summary, we report that cyclobenzaprine, at a dose 
of 30 mg/day, is effective in reducing tinnitus severi-
ty. The present results and comparisons between trials 
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should be taken as explorative since not all trials were 
performed in the same center and no placebo effect was 
evaluated. Moreover, further studies should assess the ef-
fect of cyclobenzaprine on subjective tinnitus loudness. 
However, the fact that cyclobenzaprine high-dose treat-
ment was more efficacious than tizanidine and orphen-
adrine, being all three performed in the same center (thus 
under comparable conditions), is encouraging. Moreover, 
the longer tinnitus duration and the higher extent of pri-
or treatment resistance as compared to the other groups 
treated at the same center (tizanidine and orphenadrine) 
strongly argues against a pure unspecific placebo effect 
as an explanation for the observed results with high-dose 
cyclobenzaprine. Thus, the present work sheds light onto 
a new drug with promising results for tinnitus treatment. 
Randomized, placebo-controlled, double-blind studies of 
the use of cyclobenzaprine on tinnitus patients should 
follow this open-label exploratory trial.
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